Search
Search
About
Log in
Join
Experiences with
Ipilimumab
Posts
Communities
60 public posts
Filter results
CDK 12 mutation and Immunotherapy
I also found an ongoing trial immunotherapy trial IMPACT (NCT03570619) which combines other drugs used for immunotherapy with CDK12 (ie: Nivolumab and
Ipilimumab
) Has anyone here in the community had success on either of these trials?
I also found an ongoing trial immunotherapy trial IMPACT (NCT03570619) which combines other drugs used for immunotherapy with CDK12 (ie: Nivolumab and
Ipilimumab
) Has anyone here in the community had success on either of these trials?
MikeMartin
in
Advanced Prostate Cancer
3 months ago
KRAS G13D
The new plan is to combination of dual immunotherapy with two immunotherapy drugs nivolumab and
ipilimumab
. Has anyone gone through a similar journey when 1st line treatment didn't work and pivoted?
The new plan is to combination of dual immunotherapy with two immunotherapy drugs nivolumab and
ipilimumab
. Has anyone gone through a similar journey when 1st line treatment didn't work and pivoted?
CuteLabrador123
in
Lung Cancer Support
1 year ago
Severe reaction to immunotherapy
Hi My husband has mesothelioma and has been having immunotherapy (
Ipilimumab
and Nivolumab) every 3 weeks since early January this year.
Hi My husband has mesothelioma and has been having immunotherapy (
Ipilimumab
and Nivolumab) every 3 weeks since early January this year.
toffeepudding
in
The Roy Castle Lung Cancer Foundation
11 months ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
EVOLUTION - Trial for the treatment of mCRPC
The purpose of the EVOLUTION trial involving 100 patients is to see if combining two drugs
ipilimumab
and nivolumab, which activate the body's own immune system, with Lu-PSMA can further improve anti-cancer effects of Lu-PSMA.
The purpose of the EVOLUTION trial involving 100 patients is to see if combining two drugs
ipilimumab
and nivolumab, which activate the body's own immune system, with Lu-PSMA can further improve anti-cancer effects of Lu-PSMA.
marnieg46
in
Advanced Prostate Cancer
2 years ago
Recurrent PC
Yervoy® (
ipilimumab
), an anti-CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) monoclonal antibody drug that works to enhance the immune response by targeting a subset of T-cells called Tregs that inhibit the immune response. 5.
Yervoy® (
ipilimumab
), an anti-CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) monoclonal antibody drug that works to enhance the immune response by targeting a subset of T-cells called Tregs that inhibit the immune response. 5.
marmigs
in
Advanced Prostate Cancer
2 years ago
Update
He started
ipilimumab
on November 23rd, 2021. Onco said we will not see fast results like some other drugs like Keytruda and Taf/Mek. A little nerve racking because of course time isn’t on our side. He has a high tumor burden. I would attach some pictures of his arm but it may be too much for some.
He started
ipilimumab
on November 23rd, 2021. Onco said we will not see fast results like some other drugs like Keytruda and Taf/Mek. A little nerve racking because of course time isn’t on our side. He has a high tumor burden. I would attach some pictures of his arm but it may be too much for some.
kellyOd
in
Melanoma Caregivers
2 years ago
It is likely mRNA technology is going to be what cures cancer in the next 5 to 10 years
Allison M D Anderson and Houston Methodist world leaders in immuno therapy research … check point inhibitors –
Ipilimumab
(Yervoy) Keytruda etc. before anyone in medicine thought the immune system could kill cancer.
Allison M D Anderson and Houston Methodist world leaders in immuno therapy research … check point inhibitors –
Ipilimumab
(Yervoy) Keytruda etc. before anyone in medicine thought the immune system could kill cancer.
George71
in
Advanced Prostate Cancer
2 years ago
Is this news to anybody?
A new treatment for terminal head and neck cancer patients - combining two immunotherapy drugs, nivolumab and
ipilimumab
. The CheckMate 651 trial, funded by Bristol Myers Squibb - showed especially good results in tumors with high levels of a marker called PD-L1.
A new treatment for terminal head and neck cancer patients - combining two immunotherapy drugs, nivolumab and
ipilimumab
. The CheckMate 651 trial, funded by Bristol Myers Squibb - showed especially good results in tumors with high levels of a marker called PD-L1.
kapakahi
in
Advanced Prostate Cancer
3 years ago
Duke "CHAMP" trial update
carboplatin, cabazitaxel, nivolumab and
ipilimumab
combined to slow advanced prostate cancer? Answer: We don't know yet. My PSA numbers have dropped significantly, but I'm very advanced so they dance around a bit. Lower overall but they jump back up at times.
carboplatin, cabazitaxel, nivolumab and
ipilimumab
combined to slow advanced prostate cancer? Answer: We don't know yet. My PSA numbers have dropped significantly, but I'm very advanced so they dance around a bit. Lower overall but they jump back up at times.
HerbieP
in
Advanced Prostate Cancer
2 years ago
Neuroendocrine Prostate Cancer [NEPC]
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with
Ipilimumab
in Small-Cell Lung Cancer. Cancer Cell 2019;35:329. [Crossref] [PubMed] Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with
Ipilimumab
in Small-Cell Lung Cancer. Cancer Cell 2019;35:329. [Crossref] [PubMed] Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.
pjoshea13
in
Advanced Prostate Cancer
2 years ago
Another update
Dr wants to order
ipilimumab
because it targets different cells than Keytruda was. And that will be the next treatment if this doesn’t work. Still have some things in mind that we will discuss at his appt this upcoming week. He is in so much pain.
Dr wants to order
ipilimumab
because it targets different cells than Keytruda was. And that will be the next treatment if this doesn’t work. Still have some things in mind that we will discuss at his appt this upcoming week. He is in so much pain.
kellyOd
in
Melanoma Caregivers
3 years ago
Good morning sir!
It's a hellava long infusion, premeds, nivolumab,
ipilimumab
, cabazitaxel, and carboplatin - with gaps in between for observation. I had no odd side effects besides a brief 1 minute flush feeling on the back of my neck. Total 7 hours.
It's a hellava long infusion, premeds, nivolumab,
ipilimumab
, cabazitaxel, and carboplatin - with gaps in between for observation. I had no odd side effects besides a brief 1 minute flush feeling on the back of my neck. Total 7 hours.
HerbieP
in
Advanced Prostate Cancer
3 years ago
CHAMP Clinical Trial Time for this kid
Given my prostate has evolved to Gleason 10 and neuroendocrine (small cell) I'm in the process of qualifying for the CHAMP trial: Nivolumab,
ipilimumab
, cabazitaxel and carboplatin.
Given my prostate has evolved to Gleason 10 and neuroendocrine (small cell) I'm in the process of qualifying for the CHAMP trial: Nivolumab,
ipilimumab
, cabazitaxel and carboplatin.
HerbieP
in
Advanced Prostate Cancer
3 years ago
Duke CHAMP clinical Trial Update
I've had my first infusion of the two chemos cabazitaxel and carboplatin and two immuno-therapies (nivolumab and
ipilimumab
) 14 days ago. My side effects have been less than what docetaxel were.
I've had my first infusion of the two chemos cabazitaxel and carboplatin and two immuno-therapies (nivolumab and
ipilimumab
) 14 days ago. My side effects have been less than what docetaxel were.
HerbieP
in
Advanced Prostate Cancer
3 years ago
Nivolumab + Ipilimumab for MCRPC
How are these drugs administered? Is a genetic component more reactive to this therapy. Does this show promise?
How are these drugs administered? Is a genetic component more reactive to this therapy. Does this show promise?
ronton2
in
Advanced Prostate Cancer
3 years ago
Mixed Results for Immunotherapy in Metastatic Prostate Cancer
"Ten of 35 (28.6%) patients responded to the combination of nivolumab (Opdivo) and
ipilimumab
(Yervoy). The activity fell short of the 40% threshold for a positive outcome but well above the historical response rate for immunotherapy in patients previously treated with docetaxel."
"Ten of 35 (28.6%) patients responded to the combination of nivolumab (Opdivo) and
ipilimumab
(Yervoy). The activity fell short of the 40% threshold for a positive outcome but well above the historical response rate for immunotherapy in patients previously treated with docetaxel."
snoraste
in
Advanced Prostate Cancer
3 years ago
Scan update
I believe the clinical trial involves Keytruda plus
ipilimumab
. Other trials have tried nivolumab and
ipilimumab
- but not Keytruda with
ipilimumab
. I will get details of these other treatment options and let you guys know to see if it’s something that could be useful to the community.
I believe the clinical trial involves Keytruda plus
ipilimumab
. Other trials have tried nivolumab and
ipilimumab
- but not Keytruda with
ipilimumab
. I will get details of these other treatment options and let you guys know to see if it’s something that could be useful to the community.
kellyOd
in
Melanoma Caregivers
4 years ago
'Negative' Trial Shows OS Benefit in mCRPC
"Consistent advantage at 2 to 5 years for post-RT
ipilimumab
versus placebo" https://www.medpagetoday.com/hematologyoncology/prostatecancer/88936?
"Consistent advantage at 2 to 5 years for post-RT
ipilimumab
versus placebo" https://www.medpagetoday.com/hematologyoncology/prostatecancer/88936?
snoraste
in
Advanced Prostate Cancer
4 years ago
Dual Immunotherapy Prolongs Survival While Avoiding Chemotherapy in Malignant Pleural Mesothelioma
Data from a prespecified interim analysis, based on a minimum follow-up of 22 months, showed that combined treatment with nivolumab and
ipilimumab
yielded a 4-month improvement in median overall survival (OS) as compared with platinum doublet chemotherapy (18.1 vs 14.1 months; hazard ratio [HR] 0.74,
Data from a prespecified interim analysis, based on a minimum follow-up of 22 months, showed that combined treatment with nivolumab and
ipilimumab
yielded a 4-month improvement in median overall survival (OS) as compared with platinum doublet chemotherapy (18.1 vs 14.1 months; hazard ratio [HR] 0.74,
2greys
in
Lung Conditions Community Forum
4 years ago
Hope to be helpful
Entered a trial treatment which has since been approved,
Ipilimumab
. For a few years after I continued my foolish behavior like nothing happened. 2018, my melanoma had evolved to stage 4 metastatic and we had no idea.
Entered a trial treatment which has since been approved,
Ipilimumab
. For a few years after I continued my foolish behavior like nothing happened. 2018, my melanoma had evolved to stage 4 metastatic and we had no idea.
Ryan2
in
Young Adults with Melanoma
4 years ago
1
2
3
Next page
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
37 results
Melanoma Caregivers
6 results
Lung Cancer Support
3 results
View top 10 communities
Sort by
Most Relevant
Newest